Sanofi Pasteur meets US flu vacc delivery target, promises more
Sanofi Pasteur, the vaccines business of French drug major Sanofi-Aventis, has announced that it has completed delivery of 50 million doses of its Fluzone influenza vaccine to the USA. The news means that the Lyon-based vaccine specialist firm has met its 2006-2007 flu season production plans.
On the occasion of US National Influenza Vaccination Week (November 27 to December 3), Sanofi Pasteur said it would deliver approximately three or four million extra doses to the US market in December.
The first batches of the 2006-2007 flu vaccine were shipped in August this year. Sanofi explained that it operated a multi-phased delivery process, to guarantee that all its customers received at least partial delivery of their orders by September. The vaccine manufacturer noted that, while this distribution method was more time-consuming and costly for the firm, it allows for priority patients to receive early immunization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze